Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.
In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoy...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23671696/?tool=EBI |
| _version_ | 1818460094016258048 |
|---|---|
| author | Subroto Chatterjee Nezar Alsaeedi Jennifer Hou Veera Venkata Ratnam Bandaru Lan Wu Marc K Halushka Roberto Pili Georges Ndikuyeze Norman J Haughey |
| author_facet | Subroto Chatterjee Nezar Alsaeedi Jennifer Hou Veera Venkata Ratnam Bandaru Lan Wu Marc K Halushka Roberto Pili Georges Ndikuyeze Norman J Haughey |
| author_sort | Subroto Chatterjee |
| collection | DOAJ |
| description | In a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer. |
| first_indexed | 2024-12-14T23:24:47Z |
| format | Article |
| id | doaj.art-57d8c0665a9c4073b4e5fa2fe80c1ac4 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T23:24:47Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-57d8c0665a9c4073b4e5fa2fe80c1ac42022-12-21T22:43:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6372610.1371/journal.pone.0063726Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.Subroto ChatterjeeNezar AlsaeediJennifer HouVeera Venkata Ratnam BandaruLan WuMarc K HalushkaRoberto PiliGeorges NdikuyezeNorman J HaugheyIn a xenograft model wherein, live renal cancer cells were implanted under the kidney capsule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accompanied with a 32-fold increase in the level of lactosylceramide (LacCer). Mice fed D- threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: β-1,4-GalT-V), showed marked reduction in tumor volume. This was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (GlcCer) level. Mechanistic studies revealed that D-PDMP inhibited cell proliferation and angiogenesis by inhibiting p44MAPK, p-AKT-1 pathway and mammalian target for rapamycin (mTOR). By linking glycosphingolipid synthesis with tumor growth, renal cancer progression and regression can be evaluated. Thus inhibiting glycosphingolipid synthesis can be a bonafide target to prevent the progression of other types of cancer.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23671696/?tool=EBI |
| spellingShingle | Subroto Chatterjee Nezar Alsaeedi Jennifer Hou Veera Venkata Ratnam Bandaru Lan Wu Marc K Halushka Roberto Pili Georges Ndikuyeze Norman J Haughey Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS ONE |
| title | Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. |
| title_full | Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. |
| title_fullStr | Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. |
| title_full_unstemmed | Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. |
| title_short | Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. |
| title_sort | use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23671696/?tool=EBI |
| work_keys_str_mv | AT subrotochatterjee useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT nezaralsaeedi useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT jenniferhou useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT veeravenkataratnambandaru useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT lanwu useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT marckhalushka useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT robertopili useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT georgesndikuyeze useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel AT normanjhaughey useofaglycolipidinhibitortoamelioraterenalcancerinamousemodel |